Safety and effectiveness of capmatinib in patients with unresectable advanced/recurrent non-small cell lung cancer with MET ex14 skipping alterations: a post-marketing surveillance in Japan
Safety and effectiveness of capmatinib in patients with unresectable advanced/recurrent non-small cell lung cancer with MET ex14 skipping alterations: a post-marketing surveillance in Japan. // JAAD International. – URL: https://www.sciencedirect.com/science/article/pii/S3117504X26000537?dgcid=rss_sd_all
Safety and effectiveness of capmatinib in patients with unresectable advanced/recurrent non-small cell lung cancer with MET ex14 skipping alterations: a post-marketing surveillance in Japan. JAAD International. https://www.sciencedirect.com/science/article/pii/S3117504X26000537?dgcid=rss_sd_all
“Safety and effectiveness of capmatinib in patients with unresectable advanced/recurrent non-small cell lung cancer with MET ex14 skipping alterations: a post-marketing surveillance in Japan.” JAAD International.
@article{article5812,
title = {Safety and effectiveness of capmatinib in patients with unresectable advanced/recurrent non-small cell lung cancer with MET ex14 skipping alterations: a post-marketing surveillance in Japan},
journal = {JAAD International},
url = {https://www.sciencedirect.com/science/article/pii/S3117504X26000537?dgcid=rss_sd_all}
}